In nonclinical primate and rat studies, eflapegrastim demonstrated greater biologic activity than pegfilgrastim at reducing neutropenia, at one‐third the G‐CSF dose of pegfilgrastim.8, 9. This evidence concerns the gene CSF3 and neutropenia.